Regulator fines Samsung BioLogics, calls for CEO to be fired

15 November 2018
2019_biotech_test_vial_discovery_big

Despite the market’s earlier optimism, the wild ride for investors in Samsung BioLogics (KS: 207940) continued on Wednesday, after South Korea’s financial watchdog found that the firm had intentionally broken accounting rules.

The company's woes began in May, after questions were raised about a dramatic turnaround in its fortunes, from consecutive annual losses to a sudden net profit of nearly $2 billion in 2015, in the runup to its IPO in 2016.

The Securities and Futures Commission (SFC) started a probe into the accounting irregularities, which has now delivered its verdict.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology